Jazz Pharmaceuticals plc (JAZZ) — Financial statements
Income statement, balance sheet, and cash flow for Jazz Pharmaceuticals plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 4,268↑4.9% | 4,069↑6.1% | 3,834↑4.8% | 3,659↑18.3% | 3,094 | |
| Cost of Revenue | 503↑12.9% | 446↑2.3% | 436↓19.4% | 541↑22.6% | 441 | |
| Gross Profit | 3,764↑3.9% | 3,623↑6.6% | 3,399↑9.0% | 3,119↑17.5% | 2,653 | |
| Operating Expenses | ||||||
| R&D Expenses | 783↓11.5% | 884↑4.0% | 850↑43.9% | 590↑16.7% | 506 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 1,809↑30.6% | 1,385↑3.1% | 1,343↓5.2% | 1,417↓2.4% | 1,452 | |
| Other Expenses | 948↑48.7% | 637↑1.6% | 627↓46.7% | 1,177↑123.9% | 526 | |
| Operating Expenses | 3,540↑21.8% | 2,907↑3.1% | 2,820↓11.4% | 3,184↑28.2% | 2,483 | |
| Total Costs & Expenses | 4,043↑20.6% | 3,352↑3.0% | 3,256↓12.6% | 3,725↑27.4% | 2,924 | |
| Operating Results | ||||||
| Operating Income | 224↓68.7% | 717↑23.9% | 579↑983.0% | -66↓138.5% | 170 | |
| Depreciation & Amortization | 542↓17.9% | 660↑3.3% | 639↑1.5% | 629↑13.9% | 552 | |
| EBITDA | 108↓92.9% | 1,522↑5.0% | 1,449↓1.3% | 1,469↑42.9% | 1,028 | |
| EBIT | -434↓150.3% | 862↑6.3% | 811↓3.4% | 839↑76.6% | 475 | |
| Interest & Other Income | ||||||
| Net Interest Income | -195↑18.1% | -238↑17.7% | -289↓0.4% | -288↓3.4% | -279 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 195↓18.1% | 238↓17.7% | 289↑0.4% | 288↑3.4% | 279 | |
| Non-Operating Income | 658↑553.7% | -145↑37.5% | -232↑74.3% | -905↓196.6% | -305 | |
| Other Income / Expenses | -853↓244.0% | -248↑12.6% | -284↑10.6% | -317↓11.7% | -284 | |
| Income Before Tax | -629↓234.1% | 469↑58.9% | 295↑177.1% | -383↓237.0% | -114 | |
| Income Tax Expense | -272↓198.0% | -91↑23.8% | -120↑24.4% | -159↓173.4% | 216 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -356↓163.6% | 560↑35.0% | 415↑285.1% | -224↑32.0% | -330 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -356↓163.6% | 560↑35.0% | 415↑285.1% | -224↑31.9% | -329 | |
| Bottom-Line Net Income | -356↓162.4% | 571↑29.8% | 440↑296.2% | -224↑32.0% | -330 | |
| EPS (Basic) | -5.84↓164.5% | 9.06↑38.3% | 6.55↑283.0% | -3.58↑35.0% | -5.51 | |
| EPS (Diluted) | -5.84↓167.5% | 8.65↑41.8% | 6.10↑270.4% | -3.58↑35.0% | -5.51 | |
| Weighted Average Shares | 61↓1.4% | 62↓2.3% | 63↑1.2% | 63↑4.8% | 60 | |
| Weighted Average Diluted Shares | 61↓7.6% | 66↓8.4% | 72↑15.2% | 63↑4.8% | 60 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.